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Background. Whole medicine and health systems like traditional and complementary medicine systems (T&CM) are part of
healthcare around the world. One key feature of T&CM is its focus on patient-centered andmultimodal care and the integration of
intercultural perspectives in a wide range of settings. It may contribute to good health and well being for people as part of the
Sustainable Development Goals of the United Nations.)e authentic, rigorous, and fair evaluation of such a medical system, with
its inherent complexity and individualization, imposes methodological challenges. Hence, we propose a broad research strategy to
test and characterize its possible contribution to health. Methods. To develop a research strategy for a speciﬁc T&CM system,
Anthroposophic Medicine (AM), applying multimodal integrative healthcare based on a four-level concept of man, we used a
three-phase consensus process with experts and key stakeholders, consisting of (1) premeeting methodological literature and AM
research review and interviews to supplement or revise items of the research strategy and tailor them to AM research, (2) face-to-
face consensus meetings further developing and tailoring the strategy, and (3) postmeeting feedback and review, followed by
ﬁnalization. Results. Currently, AM covers many ﬁelds of medical specialties in varied levels of healthcare settings, such as
outpatient and inpatient; primary, secondary, and tertiary care; and health education and pedagogy. It is by deﬁnition integrated
with conventional medicine in the public healthcare system. It applies speciﬁc medicines, nursing techniques, arts therapies,
eurythmy therapy, rhythmical massage, counseling, and psychotherapy, and it is provided by medical doctors, nurses, therapists,
midwives, and nutritionists. A research strategy authentic to this level of complexity should comprise items with a focus on (I)
eﬃcacy and eﬀectiveness, divided into (a) evaluation of the multimodal and multidisciplinary medical system as a whole, or of
complex multimodal therapy concept, (b) a reasonable amount of methodologically rigorous, conﬁrmatory randomized con-
trolled trials on exemplary pharmacological and nonpharmacological therapies and indications, (c) a wide range of interventions
and patient-centered care strategies with less extensive formats like well-conducted small trails, observational studies, and high-
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quality case reports and series, or subgroup analyses from whole-system studies, or health service research; (II) safety; (III)
economics; (IV) evidence synthesis; (V) methodologic issues; (VI) biomedical, physiological, pharmacological, pharmaceutical,
psychological, anthropological, and nosological issues as well as innovation and development; (VI) patient perspective and
involvement, public needs, and ethics; (VII) educational matters and professionalism; and (IX) disease prevention, health
promotion, and public health.Conclusion.)e research strategy extends to and complements the prevailing hierarchical system by
introducing a broad “evidence house” approach to evaluation, something many health technology assessment boards today
support. It may provide transparent and comprehensive insight into potential beneﬁts or risks of AM. It can serve as a framework
for an evidence-informed approach to AM for a variety of stakeholders and collaborating networks with the aim of improving
global health.
1. Background
Traditional and complementary medicine (T&CM) is
broadly and increasingly used around the world [1]. )e
wide use is related to cultural aspects and health belief
models and to the needs of patients for “whole person care.”
T&CM has a strong focus in health maintenance and disease
prevention but is also frequently applied for chronic non-
communicable diseases (NCDs). Former WHO general
director Margret Chan regarded T&CM as an often-
underestimated part of health services, particularly with
regard to addressing the challenges of chronic NCDs [1–3]
that reach epidemic proportions worldwide, accounting for
two-thirds of all deaths. Chronic NCDs have a huge eco-
nomic impact and lead to high morbidity and disability
[4, 5]. Risk factors are mainly lifestyle-related [6] and are
associated with the increasing globalization. To address this
enormous health challenge, a wider perspective may be
sensible: an integration of successful health-supporting
strategies and treatments from conventional medicine and
T&CM, embedded in transcultural understanding and
collaboration. )is could increase the number of eﬀective
approaches, implement them in culturally related health
strategies, and target them to the personal values, needs, and
resources of the highly heterogeneous populations of pa-
tients. As an example, India is mitigating the disease burden
of NCDs by launching a National Health program that
includes AYUSH systems [7].
)e basis for such integrated endeavors is transparency
of eﬃcacy, eﬀectiveness, safety, ethics, economics, and
understandability of the healthcare strategies, which are the
goals of evidence-based healthcare (EBHC): decision-mak-
ing should be based on evidence, clinical expertise, and
patients’ values [8–10]. In pursuit of this goal, the devel-
opment of new health technologies is driven by systematic
research. Medicine, however, consists of many in-
terventions, procedures, and treatment systems that have
existed since long before the principles of EBHC were in-
troduced. )is applies not only to surgical, pharmacological,
and nonpharmacological interventions and general care
principles, but also to T&CM (traditional Chinese medicine
and Ayurveda, for instance, have existed for thousands of
years); self-help approaches (like teas, baths, and wraps);
healthy and disease-preventive lifestyles; and integrative
medicine (IM) overall.
IM is an umbrella concept, still being developed for the
modern and evidence-informed integration of traditional,
natural, mind-body, and complementary treatments with
conventional medicine. IM systems share the following
characteristics: emphasis on salutogenesis, the “natural
healing power” of the organism; a holistic understanding of
the human being, incorporating physical, mental, emotional,
spiritual, and social issues; a focus on lifestyle modiﬁcations;
extensive use of nonpharmacological interventions; strong
emphasis on the therapeutic relationship between practi-
tioner and patient; shared clinical decision-making sup-
ported by evidence; and the use of both conventional and
complementary treatments [11, 12]. T&CM or IM systems
comprise whole healthcare systems that have a distinct,
unique perspective on nature, the human organism, and
disease and derive their therapies accordingly [13]. Some
T&CM interventions have received wide attention in
medicine, e.g., Artemisia annua (Nobel Prize 2015 [14]),
mind-body medicine techniques like meditation [15], yoga
[16, 17], acupuncture [18], and many modern medicines
derived from natural products that were ﬁrst used in a
traditional medicine context [1–3].
T&CM methods are broadly investigated, further de-
veloped, tested, and veriﬁed using scientiﬁc methods
[2, 3, 18–20] that are supported by research networks (e.g.,
WHO, CAMbrella, NCCIH, SIO, ISCMR, ACIMH)
[1, 21–28]. )e Cochrane library lists more than 460
Cochrane reviews and more than 26,000 randomized con-
trolled trials (RCTs) on T&CM [29]. )ese often mimic
conventional mono-drug research investigating speciﬁc ef-
ﬁcacy with explanatory placebo-controlled RCTs. However,
given the speciﬁc challenges of investigating complex
therapies as well as patient-centered care, there is currently a
shift toward pragmatic research targeting comparative ef-
fectiveness of interventions as they are practiced in real-life
situations. Furthermore, the importance of patients’ sub-
jective experiences is increasingly recognized as accountable
and as necessary measures in health intervention evalua-
tions. Also patient’s healthy resources and values are seen as
essential to promote a healthy lifestyle, reduce risk factors,
and support compliance. )ese considerations lead to an
increased use of qualitative research to explore patients’
views and needs. )ey also lead to the construction of
questionnaires that assess dimensions of health care that are
of real concern for patients. A mixed-methods approach is
pursued to gather information from multiple sources
[1, 9, 21–28, 30–35].
Anthroposophic Medicine (AM) is one of the whole
healthcare systems of IM [36]. It is based on a holistic,
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system-oriented understanding of man and nature, in-
cluding disease and treatment. Its organismic concept
consists of four levels (physical organization, life processes,
soul, and spirit) and three constitutional systems (nerve-
sense, metabolic-limb, rhythmic). AM is embedded in
countrywide care systems, secondary and tertiary care
hospitals, primary health centers, and private medical
practices [36]. It applies medicines derived from plants,
minerals, and animals; nursing procedures like rhythmical
embrocations, baths, and wraps; arts therapies like music,
painting, and sculpture; movement (eurythmy) therapy;
physiotherapies such as rhythmical massage; lifestyle rec-
ommendations associated to AM philosophy concerning
nutrition, agriculture, education; and meditation and
mindfulness, psycho-spiritual counseling, and psychosocial
support. AM care is provided by certiﬁed medical doctors,
nurses, therapists, midwives, psychotherapists, and nutri-
tionists [36–38]. AM education is provided by speciﬁc
schools, universities, and other academic institutions [36].
AM has been widely investigated [36, 39, 40]; however,
additional research activities are needed: owing to the goals
of EBHC; for research-driven innovation and development
in AM therapies and strategies; and to assess whether certain
AM approaches can contribute to the management of sig-
niﬁcant healthcare problems, particularly chronic NCDs.
)ese approaches include speciﬁc treatments such as certain
nursing applications (to treat, for instance, insomnia, anx-
iety, chronic pain, osteoarthritis) [41, 42]; herbal extracts
(e.g., for skin diseases, cancer, maternity care, and atopic
diseases) [43, 44]; and eurythmy therapy (e.g., for chronic
pain, mental conditions, high risk of falling among the el-
derly) [45]. )ey also include multimodal concepts (e.g., for
fatigue and other quality-of-life issues in chronic NCDs and
chronic infections) [46, 47]; models of patient-centered care
(e.g., for pediatric diabetic care or depressive disorder)
[48–50]; community care (e.g., for chronic pain with as-
sociated multimorbidity) [51]; strategies for dealing with
fever (http://warmuptofever.org/en/) [52]; prevention
strategies (for atopic diseases and allergies) [53, 54]; and
support of self-eﬃcacy [55] and perspectives on both the
patient’s and the care provider’s needs [56, 57].
)e investigation of a whole healthcare system like AM
[13] entails a number of speciﬁc challenges:
(i) )e patient-centered vs disease-centered approach,
which is a hallmark of AM with its strong focus on
individual resources of the patients and their psy-
chological, biographical, and spiritual needs, and on
shared decision-making and support of self-eﬃcacy.
)is approach shifts the focus from study methods
that assess eﬀectiveness of therapies for average
patients sharing a particular diagnosis; rather, it
addresses the question of whether the therapy is
eﬀective for this individual patient with (potentially)
several diagnoses (in theory, highly individualized
patient-centered care can be tested as a black box in
pragmatic comparative trials, but these trials, in
addition to their exceeding complexity, lose
explanatory power, transparency, and trans-
ferability of the results) [58].
(ii) )e multimodal approach, applying several in-
terventions (including conventional and other
T&CMmethods) in the same patient, depending on
the condition. )is addresses the complexity of
chronic NCDs in particular and the frequent con-
comitant diseases.
(iii) )e large diversity of treatments: about 1000 me-
dicinal products and medicinally used natural
substances [59], as well as therapeutic approaches
like nursing approaches, arts or movement thera-
pies, and counseling. )is by far exceeds the single-
component eﬃcacy testing with one or two clinical
trials each.
(iv) )e limited number of patients “ﬁtting into” the
trials while accepting a standardized care allocated
randomly and who are not already recruited by
competing trials [60–62]. Also, the limited accep-
tance of randomization by AM care providers [62]
restricts the conductibility of large trials.
(v) )e high costs of trials (conﬁrmatory drug trials
costing 11–53 million US$, on average [63]) and
sparse funding possibilities (commercial interest
restricted to a few remedies, rare public funding,
most research being supported by foundations,
philanthropic engagement or personal commitment
of researchers). )is necessitates an eﬃcient use of
resources.
(vi) AM care is often perceived as a therapeutic process,
a “healing journey” shared by patient and practi-
tioners stemming from a spiritual “commitment”
[64] and not to be disturbed by a clinical trial design.
Speciﬁcally, as these “joined healing journeys” may
reveal perspectives for addressing unmet needs of
severely ill patients [65, 66], evaluation designs
should preserve or even uncover preferences, in-
dividualization and intercultural experience, and
potential eﬀects related to practitioner-patient
communication and rapport.
Given this complex situation and the challenges it pres-
ents, a strategic framework is sensible to test eﬃcacy, eﬀec-
tiveness, and the cost-beneﬁt ratio; to ensure safety and ethical
principles as well as real-life application; to provide trans-
parency and explore patients’ needs, views, experiences, and
the public’s interest; and to contribute potential solutions for
health challenges such as chronic NCDs. To develop this
research strategy, a consensus process was chosen in order to
incorporate diﬀerent views, expertise, and resources.
2. Development of a Consensus-Based Research
Strategy: Methodology
In developing the research strategy, we pursued a three-
phase consensus process adapted to the Guidance for
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Developers of Health Research Reporting Guidelines [67, 68]:
)is consisted of (1) premeeting literature reviews, ﬁrstly on
recommendations for investigating whole healthcare sys-
tems, and secondly on which objectives, to what extent, have
been investigated on AM up to now; this was followed by
interviews with key stakeholders to supplement or revise
items of the research strategy, to include rationale and
supporting references, and to tailor the strategy to AM
research; (2) face-to-face consensus meetings for further
developing and tailoring the strategy; and (3) postmeeting
feedback followed by ﬁnalization.
2.1. Phase I. Key items of the strategy were developed from
ﬁrst literature review. )ey were presented to, discussed with,
and supplemented by 162 key stakeholders in the ﬁeld who
fulﬁlled at least one of the following criteria: members of AM
research council; representatives of AM at academic in-
stitutions, AM physicians, or members of patients associa-
tions; researchers in the ﬁeld with diﬀerent expertise; AM
nursing and nursing scientists; arts therapists; representatives
of AM supporting foundations; pharmacists (including AM-
related pharma executives and research or medical directors);
AM contact persons for regulatory agencies; and medical
educators (including lecturers with university academic ap-
pointments). Stakeholders included healthcare practitioners
employed in a conventional non-AM medical setting, and
medical directors of units/departments within a conventional
setting where AM is being newly implemented. Countries
represented were Germany, Italy, Switzerland, Great Britain,
Hungary, Sweden, Slovenia, Spain, South Korea, Netherlands,
Israel, Russia, USA, Brazil, Chile, Peru, Argentina, and India.
2.2. Phase 2. )e face-to-face consensus meeting at the
International Research Council in Dornach, Switzerland
(September 2017), included 25 participants. )e meeting
began with a review and discussion of the recommendations
elicited during the literature review and interviews of Phase
1. )ese recommendations were clariﬁed, further justiﬁed,
modiﬁed, or new details were added. Additionally, the
strategy was presented and discussed at two conferences in
Filderstadt, Germany (May 2017), and Dornach, Switzerland
(March 2018), including 45 and 107 international experts on
AM research and practice, respectively.
2.3. Phase 3. )e draft strategy was reﬁned and sent for
review to the AM Research Strategy Group (n� 48). )e
ﬁnalized strategy incorporated the feedback from this group.
3. Results: An Integrative Research Strategy
Just as AM covers many ﬁelds in healthcare, nearly all
medical specialties, in diﬀerent settings (outpatient, in-
patient; primary, secondary, tertiary care; private practice or
within the public health insurance system; acute and chronic
conditions; medical prevention; health education and ped-
agogy) with the help of a wide variety of healthcare providers
and training specialties, the ﬁeld of active research is
widespread.
)erefore, an integrative evaluation strategy is seen as
sensible and has already been implicitly pursued. A reasonable
amount of methodologically rigorous conﬁrmatory RCTs on
exemplary therapies and indications should be conducted.
However, the majority of interventions should be assessed in
system evaluations and smaller studies. Research on bio-
medical, physiological, pharmacological, psychological, an-
thropological, and nosological issues provides insight into
treatment and care processes and also into patients’ per-
spectives, goals, and achievements. )e diﬀerent sources of
information around this strategy address individual in-
terventions and also the complexity, diﬀerent core aspects,
and challenges of the whole healthcare system and the patient-
centered approach. Loss of important information using only
one design is minimized, as the speciﬁc focus and strength of
each design complement those of others. )us, by merging
diﬀerent designs and results, a comprehensive “evidence
house” will be possible, with diﬀerent parts serving as pieces of
a puzzle to complete a whole picture.
)e strategy could be a framework for
(i) Researchers investigating AM and T&CM, assessing
or discussing AM, collaborating internationally
(ii) Care providers participating in, supporting,
informing, or presenting research
(iii) )e medical community in general, professional
organizations, medical directors for information,
transparency, dialogue, and decision-making
(iv) Authorities, regulating AM
(v) Health policy and prevention policies imple-
menting research results
(vi) Private and public funders, pharmaceutical com-
panies funding research
(vii) Patients and their relatives and representatives,
advocacy groups
(viii) Students and educational organizations (e.g.,
universities) with interest in T&CM
(ix) )e public, civil organizations, via public relations
and journalism
)e methodological aspects of the strategy are outlined in
the following section, supplemented by examples of previous
and current AM research. )e details are exemplary and will
have to be adapted based on resources, research results, re-
search methods, quality standards and administrative re-
quirements, healthcare issues and health policy, funding
policies, and the resources and interests of researchers.
)e strategy refers to the research on (I) eﬃcacy/eﬀec-
tiveness; (II) safety; (III) economics; (IV) evidence synthesis;
(V) methodological issues; (VI) biomedical, physiological,
pharmacological, pharmaceutical, psychological, anthropo-
logical, and nosological issues as well as innovation and
development; (VII) patient perspective and involvement,
public needs, and ethics; (VIII) educational matters and
professionalism; and (IX) disease prevention, health pro-
motion, and public health.
4 Evidence-Based Complementary and Alternative Medicine
3.1. Eﬃcacy/Eﬀectiveness
3.1.1. Evaluation of the Multidisciplinary Health System as a
Whole, or of Complex Multimodal =erapy Concepts. A
system evaluation, rather than assessing a speciﬁc remedy or
treatment modality, approaches the entire complex, multi-
disciplinary, and multimodal treatment procedure. It is a
“black box” approach to the whole treatment system or to
speciﬁc multimodal therapy concepts and does not primarily
diﬀerentiate the eﬀects of the singular interventional ele-
ments. System evaluation studies assess several interventions
that are simultaneously applied (for instance [46]) and/or
individually tailored (for instance [62, 69, 70]). )ese studies
can investigate established multimodal AM treatment
concepts for relevant conditions (like rheumatoid arthritis
[71] or cancer-related fatigue [46]) applied across all pa-
tients, and individually adapted to meet the patients’
strengths and limitations. Outcomes can be disease-speciﬁc
or more general PROMs (e.g., health-related quality of life)
or patient-generated (e.g., MYMOP [72]). Such studies can
also investigate the whole system of AM, for instance in
patients with one or more chronic conditions (e.g.,
[69, 70, 73]), but also with acute diseases (e.g., [62]), di-
agnosed, treated, and counseled within the AM un-
derstanding of man and nature. Hereby, the healthcare
providers’ diagnostic and therapeutic abilities are also a
major part of the “black box.” Depending on the conditions
included, possible outcomes can be more generic, like a
disease score or survival (e.g., in cancer), or patient-gen-
erated, or health-related quality of life, but also disease-
speciﬁc outcomes in subgroups with a speciﬁc condition (as
in the Anthroposophic Medicine Outcome Study, AMOS
[69, 70]). )ese studies can also investigate certain care
models, particularly for chronic diseases (e.g., depression
[50] or community care models [51]), or speciﬁc patient-
centered care models (like patient-centered diabetic care
[48, 49]). )e evaluation methods acknowledge the multi-
level nature of many diseases and the individual presentation
of diseases in most patients and the necessity for a multi-
modal and individualized therapeutic approach
[1, 9, 21–28, 30–34, 74]. For such evaluations, diﬀerent study
designs can be chosen depending on the patient groups,
interventions, controls, and contexts: comparative eﬀec-
tiveness studies, observational research (potentially using a
bias suppression analysis or systematic outcome comparison
as used in AMOS [75, 76]), experimental designs, pragmatic
trials [69, 70], preference-based trials, quasiexperimental
designs (using for instance interrupted time-series, in-
strumental variable analysis, regression discontinuity ana-
lyses, as reviewed in [77, 78]), or health services research
[79]. In several of these designs, also matched-pair com-
parisons, synthetic controls and other regression techniques
can be applied.
)ese evaluations require a good deal of methodological
competence, knowledge, experience, and collaboration.
Detailed a priori planning in this ﬁeld is limited as it depends
on the individual researcher and on opportunities to con-
duct such studies and available funding. A prespeciﬁed plan
for the analysis and public protocol registration is strongly
encouraged, whenever possible, using common databases
such as ClinicalTrials.gov.
3.1.2. Exemplary Interventions in Certain Indications: Con-
ﬁrmative Randomized Clinical Trials. A variety of speciﬁc
AM interventions are well established and widely regarded
as beneﬁcial in certain health conditions. )ey may also
support, independently from the AM treatment context, the
eﬀective treatment of major healthcare conditions (e.g.,
allergies, skin diseases, reducing nonindicated antibiotic
prescriptions and resistance, chronic pain, mental diseases,
risk of falling in elderly, and other chronic NCDs). )e
eﬃcacy, safety, and eﬃciency of exemplary interventions
should be investigated in a reasonable and feasible number
of suﬃciently powered conﬁrmatory RCTs, with the po-
tential goal of the interventions being implemented in
treatment guidelines.
To be worthwhile for an investigation in conﬁrmative
RCTs, interventions need to meet certain conditions: they
have to have a rationale for the improvement of a relevant
health condition. )is should be supported by good
empirical data from clinical, physiological, or exploratory
studies, in order to design the trial, deﬁne outcomes,
follow-up periods, control intervention, and calculate the
sample size. )is also refers to issues of application form,
dosage, and duration. )ey should be applied in a health
condition with a need for further interventions, e.g., when
standard interventions have limited eﬃcacy, are not well
accepted by patients, or are better accepted with a
cointervention (e.g., mistletoe extracts in cancer or can-
cer-related symptoms [80, 81], NCT02948309,
NCT02106572); dermatology [44]; eurythmy therapy in
cases of high risk of falling (DRKS00016609); and nursing
procedures in pain, obstipation, nausea, sleep distur-
bance, anxiety, and others [82, 83]). Conﬁrmative RCTs
are often large, conducted in multicenter settings, as a
collaborative eﬀort of experts in diﬀerent ﬁelds (including
patient representatives) and guided by various guidelines,
standards, and national requirements. )ese trials are very
expensive and require appropriate funding and clinical
infrastructure, both of which are in relatively short supply
in AM.
3.1.3. =e Wide Range of Remaining Interventions and Pa-
tient-Centered Care Strategies: Well-Conducted Small Trials
and Observational Studies, High-Quality Case Reports and
Series, Subgroup Analyses from Whole-System Studies, and
Health Service Research. )e large quantity of AM in-
terventions and their use within a patient-centered approach
(about 1000 medicines, but also nursing procedures, arts
therapies, eurythmy therapy, massages, embrocation, packs,
teas, dietary advice, lifestyle counseling, therapeutic talks
regarding emotional, biographical, social, and spiritual is-
sues, and educational methods) exceed the current capacity
to assess these interventions in large conﬁrmative trials.
)erefore, the majority of interventions should be (and have
been) investigated or transparently presented, partly in
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smaller formats but still with high methodological quality:
for instance, observational studies and small clinical trials;
case series and case reports; subanalyses from large studies
[70, 84]; matched-pair comparisons (AM vs not AM-treated
patients); health service research (e.g., clinical registries); or
research syntheses from other similar interventions (e.g.,
non-AM Arnica preparation). Many methodological ele-
ments described above for the evaluation of health systems
can also be applied.
Altogether, many of these methods, supported by quality
standards and guidelines, are less demanding, complex, and
costly and can be conducted as smaller research projects.
Every eﬀort has to be done to enhance quality and trans-
parency and reduce the risk of bias. Still, these designs will
often not provide causal evidence and are frequently subject
to bias. )ese studies will often make use of “real-life data,”
with the primary focus sometimes switching to the point of
care, providing insights into therapeutic procedures like
patient-centered care [48] or addressing speciﬁc, unique
conditions. [42, 85] Some of these methods will be inﬂu-
enced by future speciﬁc or general developments [86–88].
3.2. Safety. With regard to safety, a variety of objectives and
methods can provide information and have been used for
investigations in AM: a key source for safety data are adverse
events and tolerability assessed within clinical trials and
studies. Another, much wider source for safety information
is pharmacovigilance studies and health service research
[59, 89]. Many side eﬀects of interventions, also rare ones,
are captured with case reports and reports from authorities
[39]. Vulnerable populations, like pregnant women, chil-
dren, or elderly, need particular attention and research—in
clinical trials, observational or pharmacovigilance studies, or
speciﬁc registries. Speciﬁc safety issues (e.g., pharmacolog-
ical interaction of AM-drugs with conventional drugs or
with other AM or T&CMdrugs [90–92]) may need a focused
investigation using diﬀerent methodologies.
Besides these classic assessments of untoward eﬀects of
interventions, also other safety issues are related to the whole
ﬁeld of T&CM as well as AM and can be investigated with
diﬀerent methodologies: for instance the impact of AM on
patients’ adherence to conventional medicine treatments
(e.g., compliance with scheduled chemotherapy protocol
[93]) and associated treatment eﬀectiveness or the impact of
AM on decreasing unjustiﬁed overuse of conventional drugs
(nonindicated antibiotics prescriptions, analgesics overuse,
etc. [51, 62, 94, 95]), to reduce drug-associated adverse ef-
fects, morbidity, and health costs [59, 71, 96–98]. A further
safety issue necessitating also exploratory research relates to
patients who adopt “alternative” health belief models that
they (wrongly) associate with AM, expressed by negation of
evidence-based conventional treatments or prevention
recommendations (e.g., certain vaccinations, antibiotics,
chemotherapy, steroids).
For the various methods, standards and guidelines exist
or have to be adapted. A large body of evidence is available
[36, 39, 59] and cooperation with national drug agencies
established.
3.3. Economics. )e economic implications of therapeutic
strategies should be evaluated [96–98]. Direct, indirect, and
intangible costs have to be considered, as well as diﬀerent
perspectives (e.g., societal, patient, and health insurance),
depending on the setting. Diﬀerent evaluation techniques
are available (e.g., cost-eﬀectiveness analysis, cost-utility
analysis, and cost-beneﬁt analysis), cost-eﬀectiveness anal-
ysis being the most common. RCTs should consider col-
lecting cost data (e.g., inpatient care, outpatient care, etc.)
and standardized quality-of-life metrics to allow an estimate
of quality-adjusted life-years (QALYs). Real-life data (reg-
istries) can be used as well in context with good quality
records. )e extent of the evaluations should be such to
capture all relevant diﬀerences regarding outcomes between
the intervention and comparators; therefore, lifetime hori-
zons using decision-analytic models are preferred [99–101].
Adopting Good Research Practices from ISPOR is highly
recommended (http://www.ispor.org). Reporting of eco-
nomic evaluations of AM should follow the standard
Consolidated Health Economic Evaluation Reporting
Standards (CHEERS) [102].
3.4. Evidence Synthesis, Systematic Reviews, andHTAReports.
)e results of eﬃcacy and eﬀectiveness research and of safety
and economic evaluations have to be systematically col-
lected, reviewed, and assessed in their methodological
quality and analyzed across individual studies. )is applies
to both single interventions on certain conditions and
complex, multimodal or individualized therapeutic systems.
)e goal would be that the strengths of and speciﬁc in-
formation gleaned from the diﬀerent designs and studies
complement each other so that the compiled data and results
form a reasonable, informative, and transparent evidence
house (which should then also include points 3.5.–3.7.).
Modeling studies can be helpful in estimating the public
health beneﬁt and costs of AM based on data from primary
or secondary sources to inform decisions on healthcare
policy [103].
For clinical trials and observational studies, the meth-
odology of systematic reviews and meta-analyses has been
developed, and widely used methods as proposed by
Cochrane and GRADE are available (http://www.cochrane.
org). For other assessment designs, complex, integrative
intervention models, case reports, etc., meta-methods like
mixed-methods reviews, critical appraisal, and evidence-
mapping remain to be fully considered or further developed.
On a broader perspective, HTA reports can be useful
[39, 40, 104].
3.5. Methodologic Issues. For many research designs,
methods and standards have been developed, and guidelines
are available to ensure quality and to deﬁne the applicability
and generalizability of the results. For other designs, such as
analyses and subanalyses, these methods have to be further
developed. )is concept relates speciﬁcally, for instance, to
“whole system” and “complex intervention” research; bias
reduction and systematic outcome comparison in large
observational studies [75, 76]; case reports [105, 106] and
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their use (e.g., applicability, strengths, weaknesses, gener-
alizability, causality, [107–109]) and their systematic as-
sessment; health service research, care models, and issues
related to clinical judgment and expertise [110], clinical
decision analysis, individualizing and patterning of clinical
responses [107, 108, 111], and “process-oriented research”
[112].
)e development of methods is carried out in close
cooperation and consensus procedures with competent
epidemiologists, statisticians, economists, methodologists,
clinical researchers, and healthcare experts in related ﬁelds.
An ongoing dialogue with decision makers, health pro-
fessional organizations, and journal editors helps to in-
corporate their views and interests.
3.6. Biomedical, Physiological, Pharmacological, Pharma-
ceutical, Psychological, Anthropological, and Nosological Is-
sues, as well as Innovation and Development. Research
should unravel the working principles of the interventions,
contribute to the transparency of the AM concepts of the
human organism and of health and disease, relate these to
other medical and scientiﬁc concepts, and further develop
medical and healthcare strategies. )is relates to AM
remedies, to understand their molecular, epigenetic, cellular,
biochemical, physiological, pathophysiological, immuno-
logical, neurological, psycho-neuro-immunological mecha-
nisms involved, the social context, etc. [43, 113, 114]. )e
same accounts to nonpharmacological interventions, life-
style changes, or counseling: do they have eﬀects on
physiological rhythms, epigenetics, the psychosocial level, or
on individual mental-cognitive developmental processes? A
key issue is speciﬁcs of dosage and application and other
pharmacological questions as well as issues of pharmaceu-
tical quality. As AM has a distinct and hierarchical concept
of the human organism that extends into nosological and
diagnostic categories, these diagnostic (practice) methods,
for instance, the constitution types of AM, have to be further
elaborated and validated.)is also includes the development
and validation of questionnaires in diﬀerent ﬁelds [115, 116].
Altogether, the anthroposophic-anthropologic concept of
the human being, nature, health, and disease (salutogenesis)
and therapy is a large ﬁeld for epistemological, conceptual,
and experimental research. )is includes the concepts of
human beings as social individuals (bio-psycho-social-
spiritual approach), of organisms as complex adaptive
systems, and of emergent behavior [117–119]. Also, AM
nursing models and concepts, widely established in practice,
can be further investigated. Last not least, these ﬁelds
connect to innovations and further development of in-
terventions within AM health care [82, 83, 114].
3.7. Patient Perspective and Involvement, Public Need, and
Ethics. )e view from the goal—investigating patients’
perspectives using AM healthcare systems or speciﬁc AM
interventions, and involving patients in research—provides
important information and is a key area in the research ﬁeld
today: patient and public needs, interests, and perspectives
on AM are assessed by qualitative and questionnaire-based
methods and systematic metaethnographic approaches
[120–122]. For clinical research, patient-relevant and ex-
perience measurements are developed (PROMS and
PREMS) [123]. First-person perspective studies, including
biographic introspection, can give important insight in
understanding the subjective dimension of disease. Patients
are increasingly involved in the development of study de-
signs and priority-setting (see http://www.invo.org.uk), also
in AM (e.g., ENTAIER trial, DRKS00016609), which is
another ﬁeld of further development. Patient involvement
and research also focuses on the development, evaluation,
and implementation of patient empowerment, patient in-
formation, and decision-making material, as well as self-care
programs using AM [49, 124, 125]. Another large ﬁeld refers
to the elements of ethics in AMhealthcare professions and in
applications of AM interventions in and outside AM and to
contributions to the general ethics discussion. )is includes
general topics of medical ethics but also the important issue
of informed consent, particularly with regard to missing
evidence or to lacks in safety data, and the issue on how to
deal with interventions or recommendations, which lack
robust evaluation.
3.8. Educational Matters and Professionalism. Educational
research provides important insights into the clinical
trainings of healthcare professionals, the quality and issues
of medical training, and the AM education, including
medical students’ possible contributions to patient-cen-
tered care [126, 127]. Furthermore, integration of AM (or
parts of it) into established healthcare systems could be
outlined and investigated, and the impact of AM courses on
medical students’ perspectives in pregraduate and post-
graduate settings could be evaluated [128, 129]; further-
more, the impact of integrative medicine training on a
mixed AM and non-AM group of practitioners, preferably
in a multidisciplinary context, could be evaluated [130], as
well as the inﬂuence of stress on burnout symptoms and
empathy of care providers and their spiritual needs
[57, 131]. Criteria for professionalism speciﬁc to AM or
T&CM physicians [132] could be further adapted for all
health professions.
3.9. Disease Prevention,Health Promotion, and PublicHealth.
AM healthcare aims to understand and support the whole
human being. )erefore, in addition to treating illnesses and
symptoms, healthy development is supported during the
entire lifetime (i.e., before, during, and after birth; during
childhood, adolescence, adulthood, and end-of-life) and also
during the development of emotional, cognitive, and spir-
itual competencies. A positive health concept is the goal
[133]. Interdisciplinary work is pivotal and also includes
consideration of pedagogy and agriculture and environ-
mental aspects. Research in these areas will depend on re-
search collaboration and networking on a large scale,
including collaboration with, for instance, epidemiologists,
healthcare insurers, and public health institutions.
[53, 54, 134].
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4. Discussion
)is research strategy covers the large spectrum of a whole
healthcare system. It encompasses an array of experimental
and explanatory to observational and pragmatic designs, from
preventive to palliative care, from intervention to the patient’s
perspective, from inpatient to outpatient care. )e ﬁelds of
basic and conceptual research and innovation also are a part
to this strategy but are only roughly outlined. )e strategy is
based on the following: existing methodological discussion of
investigating whole medical and healthcare systems including
complex interventions [1, 9, 21–28, 30–34]; what is regarded
as important by key stakeholders; and what research is ac-
tually currently pursued or planned. Future developments
may further evolve and reﬁne this strategy.
)is strategy can provide a broad view of the diﬀerent
aspects of the whole medical and healthcare system of AM
and can also support the development of speciﬁc in-
terventions or healthcare concepts that may be relevant for
healthcare in general. It also provides insight about patients’
perspectives and needs and with regard to issues of edu-
cation and professionalism. It oﬀers a framework for dif-
ferent stakeholders in medicine, science, and the general
public, and it may improve intercultural transparency. )e
pluralistic and integrative nature of the presented strategy
portends that the whole body of results will present a more
adequate perspective of the complex ﬁeld of AM than the
isolated parts would have.
)e scope of the strategy does not specify the ﬁelds
actually being the focus of research. We presume that
managing and treating chronic NCDs and focusing on
disease prevention will be of primary interest. Still, the actual
focus depends on the individual researchers and clinicians;
their institutions’ interests, capabilities, and infrastructures;
the related collaboration and networks; the potential beneﬁt
expected with the speciﬁc intervention under investigation;
and also on public interest and the priority-setting of
funders.
Four leading obstacles impede the promotion of AM
research with high-quality methodology.
4.1. External Factors. Successful high-quality research will
be impeded by budget limitations. However, even large
studies are increasingly funded, and therefore an increasing
rate of high-quality and clinically signiﬁcant research will
foster trust in AM research. Inclination of the scientiﬁc
community to embrace explanatory rather than pragmatic
trials and RCTs rather than observational and real-life
studies will impede the successful conduction, funding, and
publication of whole healthcare systems studies. However,
there is an increasing interest in a broader spectrum of
designs due to the complexity and individualization of
medicine [9, 30–34, 86–88], and therefore, high quality of
these studies as well as research on methodologic issue will
be essential.
4.2. Internal Factors. )ese relate to a limited number of
trained AM researchers and healthcare settings as well as to
potential reluctance of some AM clinicians and healthcare
providers to conduct, support, and participate in clinical
research due to workload, skepticism about research,
standardized care, and randomized treatment allocation that
conﬂicts with the individualized, patient-centered approach
they would like to employ. Close collaboration, consider-
ation of clinicians’ and healthcare providers’ needs and
constraints, and communication about the beneﬁts and risks
of research (e.g., presenting research projects and results at
AM practitioners’ conferences and integrating AM clini-
cians, healthcare providers, and patients in research plan-
ning and study design) may help to overcome these
limitations. Still, a variety of research studies, speciﬁcally
experimental, highly standardized designs like RCTs on a
speciﬁc treatment in a certain disease, will have to be
conducted outside the AM setting (e.g., NCT02948309 and
NCT02106572).
4.3. Methodologic Factors. While for RCTs a variety of
guidelines, standards, and requirements are well deﬁned,
other study types may have less rigor and less demanding
quality criteria and guidelines. )erefore, quality and
scrutiny parameters in planning, design, data quality,
analysis, presentation, careful inferences, and general
standards of good clinical research have to be strictly fol-
lowed [135–137]. Commitment by researchers and review by
ethical committees, funders, and journals still might not
ensure high quality. )erefore, the development of further
speciﬁc methodological-quality guidelines for researchers
and funders and later assessments, as well as speciﬁc
training, additional internal and external peer review, dis-
cussion within the broader network already in the planning
phase, and continuous methodological dialogue and awards
for high-quality projects, may support and improve this
approach long-term. Furthermore, the assessments of such
an area of integrative research studies, for instance with
HTA reports, may become elaborate. )is may necessitate
further methodological developments to improve pragmatic
and eﬃcient meta-assessments.
)e strength of this consensus-based strategy is the
consideration of diﬀerent dimensions of a healthcare system,
the inclusion of a large variety of stakeholders like care
providers, MDs from in and outpatient care with diﬀerent
specialties, directors of institutions or hospitals, pharma-
cists, patient representatives, funding bodies, and re-
searchers with diverse expertise and intercultural aspects.
)us, the input is based on speciﬁc scientiﬁc knowledge as
well as long practical experience with patient care, research
projects, and extensive collaboration.
Still, this consensus strategy also has some limitations. It
is a current view and does not foresee future developments,
researchers, and stakeholders, which may modify some
items of the strategy. It also does not foresee the availability
of resources and funding. )erefore, the strategy is a matter
of estimation and intention. Although the consensus process
includes many, it does not include all relevant stakeholders
outside AM, like public funders, journal editors, researchers
conducting future systematic reviews and HTA reports on
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AM or investigating other whole healthcare systems, and
authorities. However, the included stakeholders have mul-
tiple collaborations with these “external” stakeholders.
In conclusion, this strategy provides a wide spectrum of
research that will assess many facets of a whole healthcare
system pursuing patient-centered care.)is may contribute
to solutions for global health challenges, particularly with
regard to chronic NCDs and health promotion. )e culture
of collaboration with other IM and non-IMmethodologists
and researchers is of great importance and value. Re-
searchers investigating other integrative modalities such as
traditional Chinese and Ayurvedic medicine as well as
researchers investigating patient-centered care and patient-
tailored treatment (e,g. Family medicine, palliative medi-
cine, narrative-based medicine, and psycho-social-ethno
literature, spiritual care research) are confronted with some
or all of the challenges described in this article. In-
terdisciplinary and international collaboration eﬀect more
expertise and infrastructure for high-quality research
projects. Furthermore, collaboration with other stake-
holders in the healthcare system, at academic institutions,
at professional and patient organizations, with associations
and committees involved in guideline development
and healthcare planning, research, and funding, will assist
with purposeful, eﬃcient, and high-quality research
development.
5. Conclusion
T&CM, used worldwide and integrated into EBHC, can play
an important part in health services, supporting health, and
addressing chronic NCDs. Its focus is on patient-centered
care, and it is linked to the cultural background and needs
and values of patients. Transparency and information are
provided by a strong and diﬀerentiated evidence base re-
garding beneﬁt and implementation of T&CM approaches,
assessing eﬃcacy, eﬀectiveness, safety, costs, modes of ac-
tion, patient and public perspective, ethical issues, educa-
tional matters, professionalism, and healthcare procedures
and concepts. A broad research strategy, as outlined for
Anthroposophic Medicine, supports research and health-
care, transcultural understanding, and collaboration among
diﬀerent stakeholders of healthcare.
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